Selective internal radiation therapy of hepatocellular carcinoma: Potential hepatopulmonary shunt reduction after sorafenib administration

Journal of Vascular and Interventional Radiology

Volumn 23, Issue 7, 2012, Pages 949-952

  Theysohn, Jens M ^a   Schlaak, Jörg F ^a   Müller, Stefan ^a   Ertle, Judith ^a   Schlosser, Thomas W ^a   Bockisch, Andreas ^a   Lauenstein, Thomas C ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG TOLERABILITY; FATIGUE; FEMALE; HEPATOPULMONARY SHUNT; HUMAN; LIVER CELL CARCINOMA; MALE; MEASUREMENT; NAUSEA; PRIORITY JOURNAL; PULMONARY SHUNT; RETROSPECTIVE STUDY; SELECTIVE INTERNAL RADIATION THERAPY;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATOPULMONARY SYNDROME; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 84862895274     PISSN: 10510443     EISSN: 15357732     Source Type: Journal    
DOI: 10.1016/j.jvir.2012.04.007     Document Type: Article

References (12)

1. Hamami ME, Poeppel TD, Muller S, et al. SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer. J Nucl Med 2009; 50:688-692.
2. Ahmadzadehfar H, Biersack HJ, Ezziddin S. Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med 2010; 40:105-121.
3. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
4. Worns MA, Weinmann A, Schuchmann M, Galle PR. Systemic therapies in hepatocellular carcinoma. Dig Dis 2009; 27:175-188.
5. Fernando J, Sancho P, Fernandez-Rodriguez CM, et al. Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli. J Cell Physiol 2012; 227:1319-1325.
6. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011; 140:1410-1426.
7. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127(5 Suppl 1): S35-S50. (Pubitemid 39423368)
8. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25-34.
9. Ngan H, Peh WC. Arteriovenous shunting in hepatocellular carcinoma: its prevalence and clinical significance. Clin Radiol 1997; 52:36-40.
10. Cabrera R, Pannu DS, Caridi J, et al. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther 2011; 34:205-213.
11. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140:497-507.e2.
12. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009; 9:1920-1928.